Catalent (Novo Holdings)
Major fill-finish and gene-therapy CDMO, acquired by Novo Holdings in 2024 with three sites transferred to Novo Nordisk.
Sterile injectables, biologics, and cell/gene therapy manufacturing; capacity shifts after the Novo deal affected some oncology sponsors.
Pages like this
not linked directly; found by shared links- CompanyOXB (Oxford Biomedica)
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyCytiva (Danaher)
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyLonza
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanyThermo Fisher Scientific
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- CompanySamsung Biologics
Shares Sterile fill-finish and lyophilisation and the tag supporting.
- CompanyCharles River Laboratories
Shares Viral vector manufacturing (lentiviral, retroviral, AAV) and the tag supporting.
- TermCDMO (contract development and manufacturing organisation)
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV).
- TechnologyGeneric oncology drug supply and shortage mitigation
Shares Sterile fill-finish and lyophilisation and the tag supporting.